About

Mr. Elam has been founding, managing and advising healthcare and technology companies for more than 30 years. 

Prior to founding Rezolute, Mr. Elam held various senior leadership positions in the industry including Senior Vice President at Nektar Therapeutics (NASDAQ: NKTR) where he ran the Pulmonary Business Unit and was instrumental in streamlining the organization and reshaping its pipeline. Prior to negotiating the sale of his division to Novartis, Mr. Elam spun two entities out of Nektar, including Aerogen in Ireland and Pearl Therapeutics, which was acquired by AstraZeneca for $1 billion. Mr. Elam also played a fundamental role in launching Savara, Inc. (NASDAQ: SVRA) where he helped shape the company’s direction and path forward with his rare disease and pulmonary expertise. Mr. Elam also was the Co-Founder and Chief Financial Officer of e2open (NYSE: ETWO), a web-based supply chain platform company serving various industries including healthcare. Early in his career, Mr. Elam was a corporate partner at the law firm of Wilson Sonsini Goodrich & Rosati, where he advised both emerging growth companies and mature corporations such as Genentech and Hewlett Packard, and negotiated several notable deals, including the sale of Steve Jobs’ company, Next, to Apple. 

Throughout his career, Mr. Elam has served on the board of directors of various healthcare companies in the US, Europe and Asia. He currently serves on the board of Rezolute and Savara. 

Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School. 

Prior to joining Rezolute in 2017 as a founding member of the management team, Dr. Roberts directed clinical development at Fibrogen, Inc., where he helped successfully launch and execute the global Phase 3 program and pharmaceutical partnership for a novel oral therapy for anemia associated with kidney disease, concluding the largest Phase 3 program ever conducted in CKD anemia, and resulting in global NDA filings and approvals. During Dr. Roberts’ tenure, Fibrogen achieved the largest biotech IPO in the previous 10 years.

From 2007 until 2012 Dr. Roberts held clinical development positions of increasing responsibility at Cymabay, Inc., where he developed novel therapies for metabolic diseases such as diabetes, dyslipidemia, NASH, and gout. His program and clinical leadership from IND through clinical proof-of-concept helped secure a global licensing and co-development agreement with a major pharmaceutical partner for a novel diabetes therapy, as well as the successful filing of a NDA for Seladelpar.

He is an inventor or author on more than 25 patents and publications in the fields of Endocrinology and Metabolism. Dr. Roberts received his B.S. in biochemistry from the University of California, San Diego and his M.D. Magna Cum Laude from Georgetown University. He completed a residency in Internal Medicine and a fellowship in Endocrinology at Stanford University Medical Center, where he also now serves as an Adjunct Associate Professor in the Division of Endocrinology.

Susan Stewart, J.D. has more than 30 years of experience in biopharmaceutical regulatory affairs and quality assurance, overseeing and developing innovative regulatory strategies and leading interactions with global health authorities for drugs and biologics aimed at addressing unmet medical needs. In addition to being an independent regulatory consultant for several years, she is chief regulatory officer for Candel Therapeutics and previously was CRO at Frequency Therapeutics and Kaleido Biosciences. Prior to that, she was senior vice president of regulatory affairs, quality and compliance at Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular Therapeutics. She also spent 13 years at Genzyme Corporation (Sanofi) in regulatory and compliance roles, including serving as vice president, regulatory affairs, after beginning her career with Abbott Laboratories in regulatory and quality positions. She is the regulatory advisor for The Termeer Foundation.

Susan received her J.D. from Concord Law School at Purdue University Global, her LL.M from the Maurice A. Deane School of Law, Hofstra University, and her B.A. from the University of Massachusetts. Sue is a Fellow of the Regulatory Affairs Professionals Society and holds both US and EU RAC certifications.

Mr. Evans has over 15 years of experience leading public and private life science companies through financial operations, investor relations, and business development activities.

Prior to joining Rezolute, he served as Chief Executive Officer of AlloRock, Inc., a biotechnology company in the cardiometabolic disease space, as well as Chief Executive Officer of Specialty Renal Products, Inc., a medical device company in the dialysis space. Previously, Mr. Evans served as Chief Executive Officer of Nephros, Inc. (Nasdaq:NEPH), and Chief Financial Officer of Nile Therapeutics, Inc. (Nasdaq:NLTX). Since 2015, Mr. Evans has been Managing Director of PoC Capital, LLC, a fund focused on investing in public life science companies.

He holds a Bachelor of Science in Chemical Engineering from Rice University, a Master of Science in Biomedical Engineering from a joint program at the University of Texas at Arlington and Southwestern Medical School, and a Master of Business Administration from the Fuqua School of Business at Duke University.

Mr. Deperro has over 25 years of experience in public and private life science companies.  As a founding management team member at Rezolute (NASDAQ: RZLT), Mr. Deperro serves as SVP Corporate Development while maintaining his long-term role as Head of Technical Operations. 

Prior to joining Rezolute, Michael served as Vice President and General Manager at AntriaBio, led CDMO manufacturing operations at Agere Pharmaceuticals and Bend Research Inc., as well as Commercial and Clinical Manufacture at Alkermes Inc. 

He holds a Bachelor of Science in Mechanical Engineering from the University of Notre Dame and was a commissioned officer in the US Army.

Erin O’Boyle joined Rezolute in 2019 with nearly 20 years of operational and management experience across all phases of development covering several therapeutic areas, including oncology, anemia, idiopathic pulmonary fibrosis, and rare disease indications. Prior to joining Rezolute, Erin worked at Fibrogen where she led all clinical outsourcing and governance activities. She successfully contracted and managed all vendors for each clinical department which supported their various programs ranging from a rare orphan pediatric study to global Phase 3 development.

Before transitioning to a clinical lead in both contracting and governance, Erin was the Head of Clinical Operations at Heron Therapeutics. During her time at Heron Therapeutics, she successfully led a clinical program from Phase 1 up through NDA approval of SUSTOL^® (granisetron), an extended-release injection, for subcutaneous use for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy. To date, this is the largest CINV program ever conducted.

Erin obtained a Bachelor’s degree in Biology from Stonehill College.

Dr. Gopal Saha has over 22 years of experience in drug development across a broad range of therapeutic areas such as endocrine, metabolic, nephrology, and oncology. Prior to joining Rezolute, Dr. Saha served as the Vice President of Clinical Development at Apollomics, Inc. and was responsible for proving clinical leadership for the global development of an oral treatment (cMET-inhibitor, TKI) for non-small cell lung cancers, glioblastoma, and other solid tumors due to a rare genetic mutation (cMET alteration). From 2013-2021, Dr. Saha played a key role at FibroGen, Inc. in the development and approval of Roxadustat (Evrenzo®, an oral HIF-PH inhibitor for treatment of renal anemia) in the EU, Japan, and China by providing clinical leadership in Phase 3 programs. Prior to FibroGen, Dr. Saha held a clinical development position at Metabolex, now Cymabay Therapeutics, from 2004 to 2013 where he developed treatments for diabetes, gout and other metabolic disorders. He holds several patents and authors more than 20 publications in the field of endocrine/metabolic, nephrology, hematology, and oncology. 

Dr. Saha earned his medical degree (MBBS) from Chittagong Medical College, Bangladesh in 1987 and he practiced medicine in South Africa before transitioning into drug development in the USA.

Dr. Hood, a long-standing member of the patient advocacy group Congenital Hyperinsulinism International, joins the Rezolute team as Senior Director & Head of Medical and Patient Affairs. She has served in various scientific and leadership capacities such as the President of the Board of Directors and Principal Investigator for the HI Global Registry. Dr. Hood’s breadth and depth of experience within the HI community will be of tremendous value in the execution of the RZ358 development program, and guide us in a direction that captures the needs of the patients and fosters collaborative relationships within the scientific community.

Dr. Hood received her undergraduate degree from Texas A&M University and MD from University of Texas-Houston Medical School. She later earned an MBA from Walden University. 

Mr. Roeseler joins Rezolute with over 20 years of commercial leadership experience in the pharmaceutical and biotechnology industry including building commercial teams in support of rare disease launches, product and lifecycle management, brand strategy and payer marketing. 

Prior to joining Rezolute, Jeff was the founder of Biocentric, LLC, where he provided strategic advice to clinical stage rare disease companies as they advanced their portfolios towards commercialization. Earlier in his career Jeff was the head of global marketing at Insmed where he led the development and global commercialization of a novel first-in-class therapy for a rare, life- threatening respiratory disease. From 2001- 2013 Jeff held various management roles of increasing responsibility across the commercial organization of Shire. During his tenure, he supported the launch of multiple blockbuster medicines and the integration of the Advanced Bio Healing acquisition. 

Jeff received his B. A. and M.B.A from Regis University in Denver, CO.

Robyn joins Rezolute with over 30 years of pharmaceutical GxP Quality experience across development, manufacturing, clinical trials, and global commercialization. She has worked at major and small pharmaceutical companies on product categories that include vaccines, long acting injectables, biologics, hormones, and antibiotics. She brings specific experience with developing phase appropriate and proportionate Quality Systems, health authority engagement, regulatory submissions, and inspectional robustness.

Robyn obtained a B.S. in biology from the University of North Carolina.

Mr. Milks joins Rezolute with over 18 years of biotech industry experience in finance and operations. Prior to joining Rezolute, Chris led the Clinical Finance team at FibroGen where he also oversaw the Clinical Outsourcing team. Earlier in his career, Chris held positions of increasing responsibility at Gilead Sciences, mostly on the Financial, Planning and Analysis team. In those roles, he supported all functions, from a finance perspective, including G&A, Sales and Marketing and Research and Development. Additionally, he managed operations for the Access and Emerging Markets team working with partners internationally to increase access to its medicines in low and middle-income countries. Chris started his career at PriceWaterhouseCoopers while working toward his CPA.

Chris received his B.S. in Accounting from Santa Clara University and his M.B.A. from Haas School of Business at the University of California, Berkeley.

Dr. Breit has worked in early-stage and clinical drug development for over 15 years.  Prior to joining Rezolute, Dr. Breit directed numerous small and large molecule preclinical development programs for the oral, inhalation and parenteral delivery of anti-cancer compounds, drugs for the treatment of inflammatory disorders as well as vaccines.  At Bend Research/Lonza Dr. Breit worked with preclinical R&D and clinical stage CMC teams at large and small pharmaceutical and biotechnology companies, advancing compounds from early preclinical development into clinical evaluation.  Challenging drug development problem statements such as early-stage compound characterization and the creation of new technologies were hallmarks of his time at Bend Research. Activities included the creation of novel drug delivery platforms (nanotechnology, polymer conjugates), spray dried engineered particles as well as the development of machine learning tools to optimize antibody manufacturing. 

Subsequent to working at Bend Research/Lonza, Dr. Breit worked as a consultant with various biotechnology companies in preclinical and clinical development, including Rezolute.  Since joining Rezolute in 2018, Dr. Breit has focused on enabling late-stage development activities for RZ358 and RZ402; he has also led efforts focused on early-stage drug creation and development.    

Dr. Breit has received industry recognition through invited lectures, publications and patents.  He received his Bachelor of Science degree from UC Santa Barbara and his Ph.D. from the College of Medicine at the University of South Alabama, his NIH funded postdoctoral fellowship was conducted while at Roche Palo Alto.  While at Roche his research focused on understanding genomic polymorphisms’ roles in complex disease states such as cancer, diabetes and obesity.